Aptamers come of age – at last

By D. Bunka, Peter G. Stockley. Nature Reviews Microbiology, 2006

676 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

siRNA delivery systems for cancer treatment. (2009, background): “polyelectrolyte complex micelles [85], (C) aptamer-linked siRNA [91].”
Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles (2010, neutral): “…evolution, technically realized by multiple randomization, selection and amplification of strongly binding sequences, resulting in an optimized strand of DNA, RNA or peptide for the target molecule with affinities comparable to antibodies (Bunka & Stockley 2006; Lu & Liu 2006; Mairal et al. 2008).”
Aptamers and Their Biological Applications (2012, background): “In 2004, the approval by the Food and Drug Administration (FDA) of Macugen, a vascular endothelial growth factor (VEGF)-specific aptamer, for the treatment of neovascular (wet) age-related macular degeneration (AMD), is a prominent landmark in the application of aptamers [8].”
Clarifying Tissue Clearing (2015, neutral): “The use of singledomain antibodies (reviewed inHolliger andHudson, 2005) or nucleic acid aptamers (reviewed in Bunka and Stockley, 2006), which are a fraction of the size of standard antibodies, can better access epitopes deep in a sample in a shorter period of time.”